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Summary Peripheral blood lymphocytes from 96 patients with non-Hodgkin's lymphoma were studied, either
at primary staging, during treatment or in follow up. The amount of surface immunoglobulin light chain per
cell was determined by direct immunofluorescence staining analysed by flow cytometry. Discrepancy between
kappa (K) and lambda (A) fluorescence profiles in the sample was considered to indicate the presence of
monoclonal cells i.e., circulating lymphoma cells. The results were correlated with routine haematological
findings, histopathology of the lymphoma and tumour burden.
Using routine haematological methods leukaemic spread was evident in 24% of the patients in our study.
Using K/A distribution analysis evidence of circulating lymphoma cells was found in an additional 27%. As
expected, the major diagnostic gain was in the low grade malignant group, where 30% of the patients with
normal peripheral blood according to standard procedures showed evidence of circulating lymphoma cells in
the K/2 distribution analysis. The corresponding gain in the high grade malignant group was 19%. In patients
with active disease but without morphological evidence of leukaemia, 37% showed abnormal KI2 distributions.
In patients in complete remission the corresponding figure was 18%. The clinical significance of small numbers
of circulating lymphoma cells is not yet understood, but a possible outlook is to use K/A distribution analysis
to increase staging precision and in the early detection of relapse.
Non-Hodgkin's lymphomas (NHL) are considered
to represent monoclonal proliferations of single
lymphoid cells (Levy et al., 1977). Recently it has
been shown that more than one clone can be
present as determined by DNA analysis and surface
immunoglobulin (slg) (Sklar et al., 1984). In the
great majority of cases in adults, the malignant
population is derived from the B cell line and thus
bear Ig on the cell surface or intracellularly
(Aisenberg & Long, 1975; Lukes et al., 1978). The
Ig produced by the cells of one B cell clone
comprises the same light chain, either kappa (K) or,
lambda (A). The normal ratio of K and A bearing
lymphocytes in man is 2: 1 (Grey et al., 1971; Garrett
et al., 1979), and a shift in the ratio indicates the
presence of a monoclonal B cell population.
Furthermore, the amount of sIg per cell in a
monoclonal population is rather homogeneous,
compared with that of a normal, polyclonal B cell
population which is very heterogeneous (Killander
et al., 1977; Slease et al., 1979). In a quantitative
analysis of the light chain distribution in a lympho-
cyte population, the monoclonal cells will appear as
a peak in the fluorescence profile of either K or A
labelled cells. In patients with NHL of B cell type, a
disturbed K/I distribution thus indicates spread of
lymphoma cells into the circulation (Ault, 1979;
Ligler et al., 1979, 1980).
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The aim of the present study was to assess the
capacity of quantitative immunofluorometry of slg
light chains for the detection of circulating
lymphoma cells and to compare these findings with
standard haematological methods (blood micro-
scopy or peripheral white blood cell count). The
results are also correlated with tumour burden to
estimate the usefulness of K/2 distribution analysis




The subjects studied were 96 patients with different
kinds of NHL, investigated, treated and followed at
the University Hospital of Lund, Sweden. In
addition, 17 patients with various benign and other
malignant diseases were studied.
In all cases diagnosis was based on a surgical
biopsy and the lymphomas were classified
according to the Kiel classification. In 19 patients
immunological typing of the lymphoma was
performed using flow cytometric quantitation of slg
in viable cell suspensions. B cell origin was
confirmed in 18 by light chain restriction. The
distribution of patients according to histopatho-
logical category is shown in Table I. The low grade
malignant group includes malignant lymphoma
(ml) lymphocytic (lc), immunocytic (ic), centrocytic
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(cc) and centroblastic/centrocytic (cb cc). The high
grade malignant group includes ml centroblastic
(cb). immunoblastic (ib) and lymphoblastic (lb).
In 22 patients the analysis was performed in
primary staging which also included physical
examination, chest X-ray, biopsies from Waldeyer's
nng, percutaneous fine needle biopsy and scinti-
graphy of the liver and spleen, CT scan of the
abdomen and pelvis, bone marrow biopsy and
aspiration, routine haematology and blood
microscopy. Staging laparotomy was not
performed.
In 74 patients the immunological analysis was
performed during treatment or in follow up. In
these patients a peripheral white blood cell count
(wbcc) was done routinely at every check up. A
differential count was performed only if the wbcc
was above the normal range (>10x1091-1). The
blood microscopy was performed at the routine
laboratory. The patient was considered to be
leukaemic if the lymphocyte count was above the
normal range (>4 x 1091-1) or if the blood smear
contained clearly abnormal lymphocytes.
After the immunological analyses had been
performed, the patients' medical records were
reviewed and clinical data collected. A majority of
the patients had been in advanced stage at
presentation. Median time from diagnosis was 30
months (1-118). To get an idea of the actual
tumour burden at the time of sampling this was
estimated roughly. Large tumour burden denotes
moderate to extensive involvement of lymph nodes
and/or extranodal site and/or bone marrow involve-
ment; minimal disease implies one or more slightly
enlarged lymph nodes or minimal extranodal lesion
and no marrow involvement. In 58 patients the
lymphoma was still active and 38 patients were
considered to be in complete remission (CR).
Evaluation of remission included adequate
diagnostic procedures of all primanrly involved sites.
Median observation since CR was established was
10 months (0-95). Chemotherapy was given in 20
patients with active disease and in 3 patients in CR
at the time of sampling.
Preparation oflymphocytes
Lymphocytes were separated from 20ml of hepari-
nised blood by gradient centrifugation (Lympho-
prep, Nygaard) at room temperature for 30min at
400g. The cells harvested from the interface were
washed twice in Dulbecco buffer solution (Oxoid
Ltd) containing 1% bovine serum albumin (BSA).
Surface Ig staining was either performed im-
mediately, or the cells were frozen overnight at
-70-C in RPMI (Flow Laboratories) containing
10% dimethylsulphoxide (DMSO) and 10% foetal
calf serum and then stored in liquid nitrogen.
Frozen cells were thawed at 37-C and washed 3
times before staining procedures.
Surface Ig staining
The cells were incubated at 37-C for 30min in
Dulbecco buffer solution (pH 7.3) containing 10%
BSA to remove surface labile serum proteins (Lobo
et al., 1975; Kumagai et al., 1975). They were then
washed once and resuspended in Dulbecco buffer
solution containing 1% BSA and 0.1% NaN3.
FITC-conjugated F(ab')2 fragments of goat anti
human K and burro anti human i. and a polyvalent
goat anti human Ig (Kallestad Laboratories Inc.)
were used at appropriate dilutions to ensure
saturating conditions. Cells (4 x 105) were incubated
with antiserum for 30min at room temperature and
then washed 3 times. The fluorescence analysis was
performed within 24h.
Flow cytometric analysis
The fluorescence analysis was done on single cell
suspensions using a flow cytometer (Ortho Cyto-
fluorograph System 50-H) with two simultaneous
laser beams. Cell size was measured in axial light
extinction using a Helium-Neon laser at 632,8nm
(0.8mW). Fluorescence excitation was performed
by an Argon-ion laser at 488 nm (200mW), and
measured in a green filter combination (515-
555nm). The sample was first studied in a cyto-
gram in a dual presentation of axial light extinction
and green fluorescence. The lymphocyte population
was selected to avoid disturbing fluorescence from
monocytes, dead cells and debris. In the selected
population the fluorescence intensity per cell was
displayed in a frequency distnrbution using 511
linear channels of increasing fluorescence on the
horizontaTl axis and the number of individual cells
within each channel on the vertical axis. Ten
thousand cells were measured in each analysis. The
frequency distributions of the amount of K and i.
per cell in the population were visually compared
by superimposing the two fluorescence profiles in a
double exposed picture (K/i. distribution). If there
was a distinct incongruity between the two-distri-
butions, the sample was considered to be abnormal.
The control (healthy blood donors) was analysed to
show the normal identity of K and i. fluorescence
profiles (Figure 1). The channel number defining
fluorescence positivity was estimated from the
control, and remained almost invariably constant
from day to day with the same gain settings. The
percentage of K and i. positive cells and the ratio
were calculated. A K:. ratio outside the range 0.5-4























Figure 1 (a) Light chain distribution (fluorescence) of
peripheral blood lymphocytes in a patient with
leukaemic centroblastic-centrocytic lymphoma. The K
and A distributions show almost complete discrepancy,
with an abnormal clone carrying K light chain. (b)
Light chain distribution of peripheral blood lympho-
cytes in a healthy blood donor, used as a control, to
show the normal identity between K and A
distributions.
Results
Immunophenotype ofthe lymphoma and the blood
lymphoidpopulation
In 19 patients immunological typing of the
lymphoma was performed. In 10 of these patients
an abnormal K/2 distribution was present in the
peripheral blood lymphocyte population. The
identified clonal marker (i.e. sIg light chain) was in
all cases the same in blood and lymphoma.
Routine haematology compared with K/2 distribution
analysis (Table I)
Twenty of the 73 patients (27%) with a normal
wbcc had abnormal K/2 distributions. Seven of
these were in CR (4 patients with ml cb/cc and 1
each of ml cc, ic and ib).
r
Of 23 patients with overt leukaemic lymphomas
as determined by standard haemotological methods,
20 had abnormal K/2 distributions. Thus 3 patients
with morphological evidence of leukaemic spread
Table I Comparison between 3 different analyses
indicating leukaemic spread of lymphoma cells in relation
to histology ofthe lymphoma
Abnormal
KIA.
Abnormal Abnormal K:2 distri-
Kiel class haematology/ ratiol butionl
(ml) total total total
lc 8/14 7/13 10/14
tl ic 2/18 3/15 5/18
3 cc 1/8 3/8 5/8 0 > cb/cc 8/36 9/36 14/36
<,, 19/76(25%) 22/72(31%) 34/76(45%)
X cb 2/5 3/5 3/5
ib 1/9 1/9 2/9
.in lb 1/6 0/6 1/6
x 4/20(20%) 4/20(20%) 5/20(25%)
Total 23/96(24%) 26/92(28%) 40/96(42%)
ml=malignant lymphoma, lc=lymphocytic, ic=
immunocytic cc=centrocytic, cb/cc=centroblastic/
centrocytic, cb=centroblastic, ib=immunoblastic, lb=
lymphoblastic.
showed normal K/2 profiles: One with ml cb/cc, one
with ml lc and one with ml ib. The patient with ml
cb/cc (no. 13) had lymphoma cells in the bone
marrow, a wbcc of 14.7 x 1091-1, a normal
lymphocyte count, 3.3 x 1091-1 but his lymphocytes
were described as abnormal. The patient with ml lc
had had a classical chronic lymphocytic leukaemia
(B-CLL) for several years. Treatment had been
started recently with Prednimustine. His lymphocyte
count was 104 x 1091-1. Although quantitative light
chain analysis showed virtually no detectable
amounts of K or A, using a polyvalent anti-human
Ig all cells stained faintly, but were clearly abnormal,
confirming B cell origin (Grey et al., 1971;
Preud'Homme & Seligmann, 1972). The patient
with ml lb was extensively diseased with enlarged
lymph nodes, bone marrow, skin and CNS involve-
ment. He was on intensive chemotherapy and
steroid treatment. His wbcc was 22x1091-1 with
1.3 x 109 lymphocytes l-'. An abundant population
of very large, atypical mononuclear cells were
negative for slg. He died shortly hereafter. His lymph-
oma was not immunologically typed.
K/2 distribution compared with K:) ratio (Table I)
In 20 patients with abnormal KIA distributions but
normal peripheral blood according to standard
morphological methods, the K:) ratio was abnormal
in 10- all in patients with active disease.
K/I ratios were normal in 3 patients with
clinically overt leukaemia and abnormal K/2
profiles. Two of these were diagnosed as lympho-
cytic lymphomas/CLL and the quantitative light162 A. JOHNSON et al.
Table Clinical and immunological data on 22 patients investigated in
primary staging
Peripheral
Histologje Microscopy of blood
Patient (MI) Immunotype Stage marrow blood K:A K/A
1 Ic A IV + + 0.01 A
2 Ic IV + + 0.54 i.
3 Ic IV + + 17.0 K
4 ic K IV + + 6.5 K
5 ic IV + + 220 K
6 ic IV + - 1.5
7 ic IV - - 12
8 ic K I - - nd
9 ic H - - nd
10 cc II - - 0.61 i
11 cb/cc IV + + 18.6 K
12 cb/cc IV + + 8.5 K
13 cb/cc IV + + 2.0 -
14 cb/cc IV + + 16.2 K
15 cb/cc A IV + + 0.05 i
16 cb/cc IV + + 0.03 A
17 cb/cc K IV + + 5.9 K
18 cb/cc IV - - 2.2 K
19 cb IV + + 0.4 A
20 ib n - - 1.1 -
21 lb IV - - 1.7
22 lb i n - - 1.8
aSee legend to Table L
nd =Not determined; - denotes normal finding K: =ratio, K/A=
distribution. K or A denotes the donal marker in the abnormal immuno-
logical analysis.
chain analysis showed very faint but unequivocal A
labelling of all the lymphocytes. The third patient
had a lymphoblastic lymphoma.
All patients with pathological K:A ratios also
showed abnormal K/A profiles.
K/A distribution in primary staging (Table II)
Five patients presented with localized disease, stage
I-H. In one of these (no. 10) the K/A distribution in
the peripheral blood was abnormal despite a
normal K:A ratio.
Seventeen patients presented with advanced
disease (stage IV). Only 4 of these were non-
leukaemic according to standard methods. In one of
these the K/A distribution analysis was abnormal,
despite a normal K:A ratio (no. 18).
Of the patients with leukaemic lymphomas, 12
were identified in the K/A distribution analysis and
11 by K:A ratio. The patient not revealed in the
immunological analyses (no. 13) has been discussed
above.
K/A distribution in patients in CR (Tables and
IV)
Thirty eight patients were in CR for a median 10
months (0-95) when the immunological analysis
Table m Abnormal K/A distributions in relation to histo-
pathology and tumour burden
Abnormal K/A distribution
total mber ofpatients
Large tumour Minimal Complete
burden disease remussion
(%) (%) (%)
Low grade ml 22/34(65) 6/11(55) 6/31(19)
High grade ml 4/9 (44) 1/4 (25) 1/7 (14)
Total 26/43(60) 7/15(47) 7/38(18)
Low grade ml=lc, ic, cc and cb/cc.
High grade ml=lb, ib and cb.
was performed. In 7/38 (18%) the K/A distribution
analysis showed evidence of circulating lymphoma
cells. In all these 7 patients the K:A ratio was
normaL None of them had had lymphoma involve-
ment of the bone marrow during their course of
disease. All but one (no. 29) had low grade
malignant lymphomas.
The patients in CR were followed for a median of
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Table IV Twenty patients with normal routine haematology but abnormal K/2 distribution -
initial staging data, data at time ofsampling and follow up
Initial staging data Data at immunological analysis
Patient Kiel classc
no. (mO Stage Marrow Tumour mass Therapy K:A K/2 CR, months
23 ic I - CR - 1.1 A 9
24 cb/cc II - CR - 2.2 K 10
25 cb/cc III - CR - 2.3 K 60
26 cb/cc I - CR - 2.3 K 95
27 cb/cc I - CR - 1.6 K 24
28 cc IV - CR - 1.5 K 49a
29 ib III - CR - 2.7 K 7b
30 lc+ib IV + large - 0.1 2
31 lc IV + minimal + 9.0 K
32 lc IV + minimal + 38 K
33 ic I - minimal + 3.1 K
34 ic IV + large - 5.1 K
35 cc II - minimal - 0.4 2
36 cc II - large - 0.6 2
37 cc IV + minimal + 0.01 2
38 cb/cc III - minimal + 4.2 K
39 cb/cc IV + large - 0.3 2
18 cb/cc IV - large - 2.2 K
40 cb IV + large + 18 K
41 ib III - large + 0.4 A
aRelapse 19 and b3 months after sampling. CSee legend to Table I. K: =ratio, K/i=
distribution, CR=complete remission.
was performed. In the group with abnormal K/2
distributions 2/7 relapsed (1 low grade ml, 1 high
grade ml) compared with 7/31 in the CR group
with normal K/A distributions (5 low grade ml, 2
high grade ml).
K/2 distribution in patients with active disease
(Tables III and IV)
This group included 22 patients analysed in primary
staging and 36 patients examined at variable times
after diagnosis. In 20 patients treatment with
chemotherapy was ongoing.
In patients with active disease 33/58 (57%)
showed abnormal K/2 patterns in the peripheral
blood. Looking only at those with normal routine,
haematology the corresponding figures were 13/35
(37%). All but 2 were in the low grade malignant
group. Eight of these 13 patients also showed
abnormal K:i ratios.
In patients with a large tumour burden 26/43
(60%) showed abnormal K/2 distributions. The
corresponding figure in the group with minimal
disease was 7/15 (47%). In patients with normal
routine haematology but abnormal K/2 distribution
the figures were 6/20 (30%) in the group with a
large tumour burden and 7/15 (47%) in the group
with minimal disease. These differences were not
significant (Chi-square test, Fischer's exact test).
Discussion
In patients with NHL of B cell type, a disturbed
K:2A ratio, or more precisely, an abnormal K/2
distribution in the lymphocyte population in the
peripheral blood, is a strong indication of
circulating lymphoma cells. This is not, however,
absolute proof, since light chain restriction in a
population is merely evidence of monoclonal cells
(Teodorescu et al., 1978; Ault, 1979). Although
identification of the idiotype would be the true
clonal marker, this is a tedious procedure,
inconvenient for routine examination.
In this study immunological classification of the
lymphoma was performed in 19/96 patients. In all
of these cases with a pathological K/2 distribution,
the identified light chain was identical in blood and
lymphoma tissue (10/19). None of the 17 patients
with various other malignant or benign diseases
showed abnormal K/2 patterns in their peripheral
blood. Thus, even if the possibility that some other
disorder might cause an immunological disturbance164 A. JOHNSON et al.
resulting in a shift in the K/A distribution cannot be
ruled out, it does seem more likely that this finding,
in a patient with a B cell malignancy, indicates
dissemination of lymphoma cells Another possible
source of error might be the presence of mono-
clonal Ig in the serum of the patients. Theoretically
such Ig could be passively adsorbed to the normal
lymphocytes, thus simulating a monoclonal
population. This does not seem to be a major
drawback, when using the preincubation procedures
described by Lobo et al. (1975). Only 8/96 patients
had an M-component identified at routine screen
electrophoresis, and 6 of these had quite normal Kl/A
patterns in their peripheral blood.
Using the K/A distribution analysis, we found
significantly higher proportions of patients with
evidence of leukaemic spread compared to routine
haematological methods - 42%/ versus 24%. These
figures have to be interpreted with some caution,
since routine haematological methods were not fully
made use of - a blood smear was performed in one
third of the patients only. Routine use of blood
smears might have revealed more cases of
leukaemia. To assess the magnitude of the error we
have reviewed the outcome of 182 differential
counts in our department in lymphoma patients
with a normal wbcc. In 7% of these there was either
a lymphocytosis or abnormal cells considered to be
evidence of leukaemia Even if this is taken into
account, it is obvious that this immunological
method to detect circulating lymphoma cells is
more sensitive than roufine hasmatology and our
results are in good agreement with those of others
using similar light chain distribution analyses (Ault,
1979; Ligler et al., 1979). An abnormal K/IA distri-
bution on peripheral blood lymphocytes was a
more common finding in patients with low grade
malignant lymphomas Almost two-thirds of these
patients showed immunological evidence of
circulating lymphoma cells. Similar results have
been reported by others (Abdul-Cader et al., 1983)
and are consitent with the fnding that these
indolent lymphomas are widely diinated
(Heifetz et al., 1980).
We had anticpated finding a correlation between
tumour mas and presence of circulating lymphoma
cells Even if the proportion of patients with
abnormal K/A patterns tended to be higher in the
group with a large tumour burden compared to
those with minimal disease, the difference was not
significant Evidently, the presence of malignant
cells in the peripheral blood was related more to
tumour type than tumour burden.
It is known that determination of K-.i ratios is
superior to conventional haematology for the
detection of leukaemic spread in B cell lymphomas
(Garrett et al., 1979). We have compared the
sensitivity of K:A ratio determinations with those of
K/IA distributions. Since K/2 distribution analysis is
in essence a light chain estimation at discrete levels
of fluorescence, it would be logical to assume that
the distribution analysis is more sensitive (Ligler et
al, 1980). When only small numbers of monoclonal
cells are present, neither the total percentage nor
the ratio of K and A positive cells will be much
changed. Moreover, the normal range of the ratio is
broad, which futher reduces sensitivity. Our data
support these ideas, since we found the K/A
distribution analysis to be a clearly more sensitive
method.
The finding of an abnormal K/A distribution in
18% (7/38) of the patients considered to be in CR
for, in some cases, several years, is of great interest.
The majority of them (6/7) had low grade
malignant lymphomas. These results might be
compatible with the current opinion that these
lymphomas are chronic diseases with a constant
relape rate over many years (McKelvey & Moon,
1977). In 17 months (median) follow up only one of
these 6 patients has relapsed. The only patient with
a high grade malignant lymphoma in CR and with
abnormal K/A distribution relapsed shortly
thereafter. In the CR group without any signs of
circulating lymphoma cells in the immunological
analysis the relapse rate was much the same 22%
(7/31). More patients and a longer period of follow
up is needed before any conclusions can be drawn.
In patients with active disease and normal
routine haematology the K/A distribution analysis
yielde a diagnostic gain in 37%. We failed to
identify three leukaemic samples by K/i distribution
analysis The first was a patient with ml cb/cc with
marrow involvement but a normal blood lympho-
cyte count One possible explanation might be that
the cells described as abnormal in the blood smear
were actually activated normal lymphocytes rather
than lymphoma cells. The second patient had a
CLL of B cell type, as determined by the analysis
of the total amount of slg. The amount of light
chain was, however, below the detectable leveL thus
yielding a negative findig in the K/A profile (Ligler
et al., 1983). In the third paient, with ml ib it
might be that the lymphoma was not of B cell
linee, sine it is known that this group also
includes T cell tumours (Habeshaw et al., 1983).
The centrocytic lymphomas comprise a small
group, not permitting too extensive condusions.
Nonetheless, it is our definite impression, that it is
in this group that we find the most striking
differences between routine haematology and K/iA
distnrbution analyses. This might reflect an inherent
feature in the behaviour of this tumour (Swerdlow
et al., 1983) or might be due to methodological
aspects. In our experience, centrocytes have a highFLOW CYTOMETRIC LIGHT CHAIN ANALYSIS 165
Ig density on the cell surface and are easily detected
by immunological analysis, although they might be
difficult to distinguish as malignant in a routine
blood smear.
The conclusion to be drawn from this study is
that quantitative light chain analysis is a more
sensitive method of detecting circulating lymphoma
cells than routine haematological methods. It is a
simple and convenient test well suited for routine
use in monitoring patients with NHL during
treatment and in follow up. The prognostic
significance of small numbers of circulating
lymphoma cells in patients in CR and in stage I
disease has yet to be ascertained. Further studies
and long term follow up is needed.
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